ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (TSE:PLI) is a biopharmaceutical business, comprised of a group of companies focused on developing technologies, which bring pharmaceutical products to market. ProMetic’s business is organized into two operating segments; protein technologies and therapeutics. The protein technologies business unit has research and development operations in Maryland, United States, and Cambridge, United Kingdom, and manufacturing operations on the Isle of Man, United Kingdom and in Joliette, Canada. It focuses on development and manufacturing of plasma-derived therapeutics, pathogen removal and diagnostics using technology and the manufacture of specialist filtration media for use in the manufacture of biopharmaceuticals. The therapeutics business unit is based in Laval, Canada. ProMetic’s therapeutic, PBI-1402, is an orally active compound developed to treat different types of anemia. Its subsidiary is ProMetic Biosciences Ltd.
News
OTC Markets Group recently launched the OTCQX Composite Index (.OTCQX), OTCQX International Index (.OTCQXINT) and OTCQX U.S. Index (.OTCQXUS), to provide investors with a benchmark of the established, global and growth companies traded on the OTCQX marketplace.
Abraxis Makes Initial $7 M US Equity Investment in ProMetic, with Future Additional Optional Equity Investments of Up to $25 M US
###
2,267 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 9) (Last 30 Days: 25) (Since Published: 2267)
